Inventor
HOWARD MAUREEN
US15 patents
⚠️ This page may combine multiple inventors who share the name “HOWARD MAUREEN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
UNIV LELAND STANFORD JUNIOR
8 patentsUS9623079B2Apr 18, 2017
Methods for achieving therapeutically effective doses of anti-CD47 agents for treating cancer
UNIV LELAND STANFORD JUNIOR26 citations97
US11136391B2Oct 5, 2021
Methods for treating cancer by achieving therapeutically effective doses of anti-CD47 antibody
UNIV LELAND STANFORD JUNIOR9 citations93
US10301387B2May 28, 2019
Methods for achieving therapeutically effective doses of anti-CD47 agents
UNIV LELAND STANFORD JUNIOR11 citations92
US11518806B2Dec 6, 2022
Methods for treating cancer by achieving therapeutically effective doses of anti-CD47 antibody
UNIV LELAND STANFORD JUNIOR6 citations84
US11603404B2Mar 14, 2023
Methods for treating cancer by achieving therapeutically effective doses of anti-CD47 antibody
UNIV LELAND STANFORD JUNIOR3 citations83
US12258399B2Mar 25, 2025
Methods for achieving therapeutically effective doses of anti-CD47 agents
UNIV LELAND STANFORD JUNIOR0 citations62
US11104731B2Aug 31, 2021
Compositions for achieving therapeutically effective doses of anti-CD47 agents
UNIV LELAND STANFORD JUNIOR0 citations62
US12258403B2Mar 25, 2025
Methods for treating myeloma by achieving therapeutically effective doses of anti-CD47 antibody
UNIV LELAND STANFORD JUNIOR0 citations61
SCHERING CORP
3 patentsUS5837232ANov 17, 1998
Use of an interleukin-10 antagonist to treat a B cell mediated autoimmune disorder
SCHERING CORP30 citations92
US5837293ANov 17, 1998
Use of interleukin-10 analogs for antagonists to treat endotoxin- or superantigen-induced toxicity
SCHERING CORP9 citations73
US5833976ANov 10, 1998
Use of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicity
SCHERING CORP9 citations72